Showing 431 - 440 of 1107 results

Showing Results for: “diabetes exercise”

The American Diabetes Association Statement on Medicaid Expansion in North Carolina

“The American Diabetes Association ® (ADA) applauds the long-awaited passage of Medicaid expansion in North Carolina. With more than 1 million people in North Carolina living with diagnosed diabetes, ADA believes this is a transformative step towards improving health access and health outcomes. An individual’s ability to manage diabetes is directly tied to his or her ability to access affordable and adequate health insurance coverage. States that have expanded Medicaid have seen a vast improvement in self-reported access to care and diabetes management, providing enrollees with vital access to

The American Diabetes Association Statement on Sanofi’s Insulin Price Cut

“The American Diabetes Association ® (ADA) is the leading voice advocating for insulin affordability and is working to ensure that all people with diabetes have access to the care they need. The ADA has led the charge to enact cost-sharing limits on insulin in 22 states and D.C., and the first-ever federal copay cap in Medicare. We are encouraged that all of the major manufacturers have taken steps to make insulin more affordable, but the fight is not over. We will continue advocating for efforts in Congress and states across the country to ensure insulin is affordable to everyone with

American Diabetes Association Statement on New CGM Study Findings

A new study released by the American Diabetes Association ® (ADA), illustrates the significant barriers that low-income Americans, people of color, older Americans, and people with diabetes living in states with the highest prevalence of the disease face in accessing continuous glucose monitors (CGM). These barriers are especially high for Americans on Medicaid, who are the least likely to have access to a CGM. CGMs continually monitor blood glucose (blood sugar), giving real-time updates. The devices provide significant, potentially life-changing benefits for diabetes management, and in turn

Once Weekly Drug Helps Control Pediatric Type 2 Diabetes

Data Shows Potential Breakthrough Treatment Option for Glucose Management in Adolescents with Uncontrolled Diabetes Findings from an international study show a once-weekly injection of dulaglutide was superior in improving glycemic control in youth with type 2 diabetes compared to placebo. The trial was presented at the 82nd Scientific Sessions of the American Diabetes Association ® (ADA) in New Orleans, LA, and simultaneously published in The New England Journal of Medicine . The findings come at a time when cases of type 2 diabetes among youth have more than doubled, since the pandemic

Know Diabetes by Heart™ Awards $900,000 for Community Education

Ten grants from the American Diabetes Association and the American Heart Association’s joint initiative aim to decrease heart disease and stroke among people with type 2 diabetes. The American Diabetes Association® and the American Heart Association® have awarded up to $900,000 to organizations to help people living with type 2 diabetes lower their risk for cardiovascular diseases like heart attack, heart failure and stroke. The community grants are part of the leading health non-profits’ joint Know Diabetes by Heart™ initiative which seeks to reduce cardiovascular events and deaths among

Insulin Co-Pays Capped at $100 for those in Vermont with Diabetes

The American Diabetes Association® applauds Vermont’s governor and legislature for passing a cap on insulin co-pays. Today, Vermont House Bill 969 was signed into law by Governor Phil Scott. The law limits cost-sharing for insulin to $100 per 30-day supply for those with state-regulated commercial health insurance, a measure supported by the American Diabetes Association (ADA). The cap applies to the enrollee’s total insulin cost, so if someone requires more than one type of insulin, their cost-sharing would still not exceed $100 in total. Stephen Habbe, Director for State Government Affairs

ADA Statement on the IDF Diabetes Atlas Global Impact Report

The American Diabetes Association ® (ADA) today released the following statement in reaction to the release of the International Diabetes Federation's (IDF) report showing a dramatic increase in the number of people worldwide who've been diagnosed with diabetes. “This data is devastating. We've been watching the steady increase in diabetes globally, and it should be a call to action for everyone. This is a public health epidemic that's been ignored for far too long. Alarming data such as 73.6 million more adults with diabetes since the onset of the pandemic, we need to take American Diabetes

American Diabetes Association Unveils #HealthEquityNow Platform to Ignite Action

As COVID-19 puts people with diabetes and minorities in the crosshairs, ADA calls for a Health Equity Bill of Rights to address systemic health inequities The American Diabetes Association® (ADA), the nation’s leading organization for all people living with diabetes, announced today the launch of #HealthEquityNow, a national platform to ensure that all people living with diabetes, and the millions of underserved Americans who are at greatest risk for diabetes, have access to health resources that are too often unavailable to them. The ADA calls on businesses, policymakers, philanthropies and

Co-Pays for Insulin and Diabetes Medications Capped at $25 in Connecticut

The American Diabetes Association® applauds Connecticut’s governor and legislature for passing a cap on co-pays for diabetes medications and supplies Recently, Connecticut House Bill 6003 was signed into law by Governor Ned Lamont. The law limits cost sharing for insulin and other diabetes medications to $25 per 30-day supply for those with state-regulated commercial health insurance. The law also caps diabetes devices and supplies at $100 per 30-day supply, allows for someone with an expired prescription to obtain insulin in an emergency, and establishes a workgroup on connecting people in

American Diabetes Association® Echoes FDA Statement on Metformin Recall

Consumers should first check with their pharmacist to see if their metformin prescription is affected The U.S. Food and Drug Administration (FDA) recently announced a recall on extended-release (ER) metformin drugs from five manufacturers due to testing results showing N-Nitrosodimethylamine (NDMA) above the acceptable intake limit in certain lots. Type 2 diabetes patients who are currently taking an ER version of metformin and are unsure if their medication is affected, should first check with their pharmacist to see if their prescribed medication is one of the five being recalled: Apotex –